Previous studies, including our own, have demonstrated that muscle sympathetic nerve activity (MSNA) is increased in patients with essential hypertension compared with normotensive subjects. However, the features of sympathetic nerve activity are still unknown in secondary hypertension. We examined MSNA in eight patients with renovascular hypertension and in 11 patients with primary aldosteronism. Twenty patients with essential hypertension and 20 normotensive subjects who were age-matched to the patients with renovascular hypertension and those with primary aldosteronism were also studied. The MSNA of a bundle of the tibial nerve was recorded by microneurography in supine subjects and expressed as both burst rate (bursts/min) and burst incidence (bursts/100 heart beats). Plasma renin activity and the plasma concentration of angiotensin II and aldosterone were also measured. MSNA was increased in the patients with renovascular hypertension compared with the patients with primary aldosteronism and those with essential hypertension and the normotensive subjects (p<0.01 for each). MSNA was decreased in the patients with primary aldosteronism compared with those with essential hypertension (p<0.01), and it was smaller than in the normotensive subjects (p<0.l). Furthermore, MSNA, plasma renin activity, and the plasma concentration of angiotensin II decreased significantly in five patients with renovascular hypertension 4-10 days after successful percutaneous renal angioplasty. Thus, the changes in MSNA seem to characterize the patbophysiology of renovascular hypertension and primary aldosteronism. Activation of the renin-angiotensin system may be involved in the increase in the central outflow of sympathetic nerve activity, thus exacerbating hypertension in patients with renovascular hypertension. (Hypertension 1991;17:1057-1062) N eurogenic mechanisms have often been implicated in the pathogenesis of hypertension. Although the plasma concentration of norepinephrine has been used as a rough index of overall sympathetic nerve activity, its pathophysiological implications need careful evaluation since the plasma concentration of norepinephrine is determined by many factors, such as the reuptake and metabolic degradation of norepinephrine and its spillover from the nerve endings.1 ' 2 Accordingly, we have investigated sympathetic tone by directly recording the muscle sympathetic nerve activity (MSNA) contained in a bundle of the tibial nerve using a microneurographic technique in the conscious human.3 -8 Our previous studies have demonstrated that the baroreflex control of sympathetic

To determine whether there may be an abnormality in sympathetic nerve activity in response to physical and psychological stressors, we microneurologically recorded muscle sympathetic nerve activity in 11 normotensive and 9 borderline hypertensive, age-matched men. Supine blood pressure, plasma levels of epinephrine and norepinephrine and muscle sympathetic nerve activity were measured before and during a cold pressor test or a mental arithmetic test. The resting basal values of muscle sympathetic nerve activity, blood pressure and plasma epinephrine were significantly higher in the borderline hypertensives than in the normotensives (P less than 0.05). Plasma norepinephrine levels tended to be higher in the borderline hypertensives than in the normotensives but not to a significant extent (P less than 0.10). The cold test produced significantly exaggerated pressor and muscle sympathetic nerve responses (P less than 0.05) with a trend towards an increase in plasma norepinephrine (P less than 0.10) in the borderline hypertensives as compared with normotensives. The mental arithmetic test produced significantly enhanced pressor and plasma epinephrine responses in the borderline hypertensives as compared with the normotensives (P less than 0.05). During the mental arithmetic test the muscle sympathetic nerve activity decreased significantly in the normotensives (P less than 0.05) but not in the borderline hypertensives. These findings indicate that in people with borderline hypertension an abnormality exists in sympathetic nerve activity at rest and in response to stressors.

The effect of angiotensin II (ANG II) on the sympathetic outflow was examined in normal humans. The mean arterial pressure and muscle sympathetic nerve activity (MSNA) were measured before and during intravenous infusions of phenylephrine (0.5 and 1.0 micrograms.kg-1.min-1) or ANG II (5, 10, and 20 ng.kg-1.min-1) for 15 min at 30-min intervals. The baroreflex slope for the relationship between the increases in mean arterial pressure and the reductions in MSNA was significantly less acute during the infusions of ANG II than during the infusions of phenylephrine. When nitroprusside was infused simultaneously to maintain central venous pressure at the basal level, MSNA significantly increased during the infusions of ANG II (5 ng.kg-1.min-1 for 15 min) but not during the infusions of phenylephrine (1.0 micrograms.kg-1.min-1 for 15 min), with accompanying attenuation of the elevation in arterial pressure induced by these pressor agents. These findings suggest that ANG II stimulates the sympathetic outflow without mediating baroreceptor reflexes in humans.

No abstract

No abstract

Angiotensin converting enzyme (ACE) inhibitors which have active moieties excreted mainly in urine require adjustment of either the dose or the interval between doses in patients with moderate to severe renal dysfunction or severe congestive heart failure. Those agents such as temocapril (CS 622) and fosinopril, excreted both in urine and bile, may not require such adjustment. Renal clearance of ACE inhibitors may be reduced and some accumulation may occur in elderly patients with mild renal dysfunction or congestive heart failure. The bioavailability of ACE inhibitors is reduced by concomitant food or antacids which may slow gastric emptying and raise gastric pH. Pharmacokinetic interactions with ACE inhibitors are unlikely in patients receiving thiazide or loop diuretics. When ACE inhibitors are given hyperkalaemia may occur in patients with renal insufficiency, those taking potassium supplements or potassium-sparing diuretics, and in diabetic patients with mild renal impairment. While no pharmacokinetic interaction precludes use of this combination, the pharmacokinetics of some ACE inhibitors are subject to greater variability when patients also receive beta-blockers. Calcium antagonists and ACE inhibitors have additive anti-hypertensive effects and pharmacokinetic interactions between these agents are unlikely. One report exists of a significant effect of coadministered hydralazine on the pharmacokinetics and urinary excretion of lisinopril. Data on interactions between ACE inhibitors and digitalis are contradictory. There is no evidence that the concomitant use of ACE inhibitors and digoxin is associated with an increased risk of digitalis toxicity. ACE inhibitors are mainly excreted by glomerular filtration and renal tubular secretion. Possible interactions between ACE inhibitors and probenecid have been noted, with renal and total body clearance of ACE inhibitors being potentially reduced in the presence of probenecid. Probenecid pretreatment may enhance the pharmacodynamic response of ACE inhibitors. Few but contradictory data exist on the effects of H2-blockers on ACE inhibitor pharmacokinetics and little information is available on interactions between ACE inhibitors and hypoglycaemic drugs. Some case reports link ACE inhibitors with the induction of lithium toxicity. Coadministration of lithium should be undertaken with caution, and frequent monitoring of lithium concentrations is recommended with all ACE inhibitors. Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the haemodynamic actions of ACE inhibitors. NSAIDs reduce renal excretion of ACE inhibitors, with a corresponding increase in circulating drug concentrations. There is little information available on the pharmacokinetic interaction with ACE inhibitors and cyclosporin, but caution should be employed when they are used together.(ABSTRACT TRUNCATED AT 400 WORDS)

We studied the effects of chronic blockade of the renin-angiotensin system on hypertension and cardiac left ventricular hypertrophy (LVH) in Dahl salt-sensitive (DS) rats given a high-salt or low-salt diet. [Experiment 1] Twelve-week-old male DS rats were fed an 8% NaCI diet and received the angiotensin II receptor (AT1) antagonist, candesartan (3 mg/kg/d), the angiotensin converting enzyme inhibitor enalapril (30 mg/kg/d), or vehicle for 6 wk after 3 wk of 8 % salt-loading. Neither candesartan nor enalapril with concomitant high salt-loading attenuated the blood pressure (BP) elevation. LVH was also not attenuated significantly by these treatments. [Experiment 2] After 8 wk of 8 % salt-loading, the rats were given a 0.3% NaCI diet and concurrently received candesartan, enalapril, or vehicle for 5 wk. Switching from the high-salt to low-salt diet significantly decreased BP and left ventricular mass in the vehicle-treated animals. Both candesartan and enalapril normalized BP during salt-depletion; the blockade of the reninangiotensin system produced an additive reduction in LVH. These findings suggest that sodium intake and hemodynamic load, but not the renin-angiotensin system, may be major determinants of the development of LVH in DS rats. Numerous studies have demonstrated that angiotensin II (Ang II) plays a key role in the development and maintenance of hypertensive cardiac hypertrophy in experimental animals and humans. Blockade of Ang II receptors inhibits intracellular signaling of stretch-mediated hypertrophy of cultured cardiomyocytes, suggesting that pure mechanical stimuli can elicit myocardial cell hypertrophy by stimulating Ang II secretion from cardiomyocytes (1). It is thus conceivable that cardiac hypertrophy caused by mechanical (hemodynamic) load alone can be reduced by Ang II receptor antagonism.Dietary high-salt intake causes cardiac hypertrophy and hypertension in Dahl salt-sensitive (DS) rats and suppresses plasma renin activity (PRA). Thus, it appears that cardiac hypertrophy in saltloaded DS rats is induced mainly by hemodynamic load, with only a small contribution from the reninangiotensin system. However, if activation of a local renin-angiotensin system (RAS) is involved in cardiac left ventricular hypertrophy (LVH), blockade of the RAS could reduce LVH even in salt-loaded DS rats. We have previously demonstrated that angiotensin type I (AT1) receptor antagonists did not blunt hypertension or reduce LVH in DS rats fed a 4% NaCI diet (2, 3).Our findings suggest that sodium intake plays a major role in the development of LVH and hypertension in salt-loaded DS rats, and that the tissue RAS might not be activated in DS rats fed a 4% NaCI diet. It has been reported that an 8% sodium loading initially suppressed PRA and then increased its value after a 4-wk period of high-salt loading in DS rats (4). These findings suggest that the circulating RAS is activated even in DS rats given an 8% NaCI diet for a longer period, and suggest the possibility that the tissue renin-angiotensin system in DS...

Slow hemodialysis (HD) was performed for 10 h during the day in 11 critically ill patients with renal failure. The dialysis method was a modification of the pump-driven continuous venovenous HD. A nonsterile bicarbonate-containing hemodialysate was passed into the EVAL membrane dialyzer at a flow rate of 30 ml/min. No patient developed further hemodynamic instability during the treatment. The serum urea level was maintained below 20 mmol/l within 4 days of initiating the treatment. It allowed the patients to rest without interruption at night. This method was safely conducted by general nursing staff under the supervision of nephrologists on duty during the day. This schedule offers an approach to renal replacement therapy for hemodynamically unstable patients without any potential problem in the extracorporeal circulation at night.